Shuichi Hirono

Minato, 1088641, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 63 publications

The Stat3 inhibitor F0648-0027 is a potential therapeutic against rheumatoid arthritis.

The Stat3 inhibitor F0648-0027 is a potential therapeutic against rheumatoid arthritis.

Journal: Biochemical and biophysical research communications

Published: October 23, 2022

Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older.

Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older.

Journal: BMC gastroenterology

Published: February 10, 2022

Synthesis and Evaluation of a Novel Series of 2,7-Substituted-6-tetrazolyl-1,2,3,4-tetrahydroisoquinoline Derivatives as Selective Peroxisome Proliferator-Activated Receptor γ Partial Agonists.

Synthesis and Evaluation of a Novel Series of 2,7-Substituted-6-tetrazolyl-1,2,3,4-tetrahydroisoquinoline Derivatives as Selective Peroxisome Proliferator-Activated Receptor γ Partial Agonists.

Journal: Chemical & pharmaceutical bulletin

Published: April 01, 2021

Identification of novel EED-EZH2 PPI inhibitors using an in silico fragment mapping method.

Identification of novel EED-EZH2 PPI inhibitors using an in silico fragment mapping method.

Journal: Journal of computer-aided molecular design

Published: November 01, 2020

Strategy for Designing Selective Lysosomal Acid α-Glucosidase Inhibitors: Binding Orientation and Influence on Selectivity.

Strategy for Designing Selective Lysosomal Acid α-Glucosidase Inhibitors: Binding Orientation and Influence on Selectivity.

Journal: Molecules (Basel, Switzerland)

Published: May 27, 2020

(S)-1,2,3,4-Tetrahydroisoquinoline Derivatives Substituted with an Acidic Group at the 6-Position as a Selective Peroxisome Proliferator-Activated Receptor γ Partial Agonist.

(S)-1,2,3,4-Tetrahydroisoquinoline Derivatives Substituted with an Acidic Group at the 6-Position as a Selective Peroxisome Proliferator-Activated Receptor γ Partial Agonist.

Journal: Chemical & pharmaceutical bulletin

Published: November 06, 2019

A 3D-QSAR Analysis of CDK2 Inhibitors Using FMO Calculations and PLS Regression.

A 3D-QSAR Analysis of CDK2 Inhibitors Using FMO Calculations and PLS Regression.

Journal: Chemical & pharmaceutical bulletin

Published: June 04, 2019

Identifying Inhibitors of USP7-HDM2 Protein-Protein Interaction (PPI) by the in Silico Fragment-mapping Method

Identifying Inhibitors of USP7-HDM2 Protein-Protein Interaction (PPI) by the in Silico Fragment-mapping Method

Journal: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

Published: March 08, 2019

Characterizing the selectivity of ER α-glucosidase inhibitors.

Characterizing the selectivity of ER α-glucosidase inhibitors.

Journal: Glycobiology

Published: December 14, 2018

Structure-based virtual screening for novel chymase inhibitors by in silico fragment mapping.

Structure-based virtual screening for novel chymase inhibitors by in silico fragment mapping.

Journal: Journal of molecular graphics & modelling

Published: December 10, 2018

2-Acyl-3-carboxyl-tetrahydroisoquinoline Derivatives: Mixed-Type PTP1B Inhibitors without PPARγ Activation.

2-Acyl-3-carboxyl-tetrahydroisoquinoline Derivatives: Mixed-Type PTP1B Inhibitors without PPARγ Activation.

Journal: Chemical & pharmaceutical bulletin

Published: December 04, 2018

Design of a New α-1-C-Alkyl-DAB Derivative Acting as a Pharmacological Chaperone for β-Glucocerebrosidase Using Ligand Docking and Molecular Dynamics Simulation.

Design of a New α-1-C-Alkyl-DAB Derivative Acting as a Pharmacological Chaperone for β-Glucocerebrosidase Using Ligand Docking and Molecular Dynamics Simulation.

Journal: Molecules (Basel, Switzerland)

Published: September 10, 2018

Showing 1-12 of 63

Last Updated: 09/26/2026